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Background: Left ventricular ejection fraction (LVEF) and infarct size (ISZ) are key 
predictors of long-term survival after myocardial infarction (MI). However, little is known 
about the biochemical pathways driving left ventricular dysfunction after MI. To identify 
novel biomarkers predicting post-MI LVEF and ISZ, we performed metabolic profiling in the 
GIPS-III randomized clinical trial. We also investigated the metabolic footprint of metformin, 
a drug associated with improved post-MI left ventricular function in experimental studies. 
 
Methods and Results: Participants were ST-elevated MI (STEMI) patients who were 
randomly assigned to receive metformin or placebo for 4 months. Blood samples were 
obtained on admission, 24 h and 4 months post-MI.  233 metabolite measures were quantified 
using nuclear magnetic resonance (NMR) spectrometry. LVEF and ISZ were assessed 4 
months post-MI. 24 h post-MI measurements of HDL triglycerides (HDL-TG) predicted 
LVEF (β=1.90 [95% CI: 0.82, 2.98]; p=6.4x10-4) and ISZ (β=-0.41; 95% CI: -0.60, -0.21]; 
p=3.2x10-5). Additionally, 24 h post-MI measurements of medium HDL-TG  (β=-0.40 [95% 
CI: -0.60, -0.20]; p=6.4x2x10-5), small HDL-TG (β=-0.34 [95% CI: -0.53, -0.14]; p=7.3x10-4) 
and the triglyceride content of very large HDL (β=-0.38 [95% CI: -0.58, -0.18]; p=2.7x10-4) 
were associated with ISZ. After the 4-month treatment, the phospholipid content of very large 
HDL was lower in metformin vs. placebo treated patients (28.89% vs. 38.79%; p=7.5x10-5); 
alanine levels were higher in the metformin group (0.46 mmol/L vs. 0.44 mmol/L; p=2.4x10-
4).  
 
Conclusions: HDL triglyceride concentrations predict post-MI LVEF and ISZ.  Metformin 
increases alanine levels and reduces the phospholipid content in very large HDL particles.  
 
Clinical Trial Registration: NCT01217307 (https://clinicaltrials.gov/show/NCT01217307) 
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Myocardial Infarction (MI) is one of the leading causes of global morbidity and mortality. 
While the survival after MI has improved due to ameliorated treatment strategies, including 
primary percutaneous interventions, the long-term outcome of MI in general remains poor 
with a 1-year risk for recurrent cardiovascular (CV) disease of over 10%.1 Left ventricular 
ejection fraction (LVEF) and infarct size (ISZ) are key predictors of long-term prognosis 
after MI.2,3. However, treatment options for left ventricular dysfunction are limited and the 
biochemical mechanisms driving functional decline of the myocardium after MI are largely 
unknown.  
Metformin, which is commonly used in the treatment of diabetes and more recently in 
insulin resistant conditions, has been found to preserve LVEF and to reduce ISZ in non-
diabetic animal models of MI.4 The GIPS-III clinical trial was designed to study the effects of 
metformin therapy on LVEF in non-diabetic ST segment Elevation MI (STEMI) patients 
undergoing PCI. However, in contrast to preclinical findings, metformin did not improve 
LVEF compared with placebo 4 months post-MI.5  
This result may be explained by interindividual differences in metformin response, raising 
the possibility that metformin is effective in a subgroup of CV patients. Metabolic profiling 
has emerged as a powerful tool to explore drug effects and factors influencing drug 
response.6-8 Metabolomics is a relatively novel field in ‘omics’ sciences, which uses high-
throughput technologies, such as nuclear magnetic resonance (NMR) spectroscopy, to 
concurrently quantify a large number of small molecules in different tissues. While recent 
studies reported changes in lipid and amino acid concentrations after metformin treatment9-11, 
no study has yet used large-scale metabolic platforms to investigate the effects of metformin 
on a wide range of metabolite measures at a time. Furthermore, metabolic profiling has been 
performed to improve diagnosis and prediction of CV events.12,13 A recent study identified 
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metabolic profiles which discriminate heart failure patients from healthy controls.14 
Metabolic profiling may thus help identify novel biomarkers of left ventricular function and 
ISZ to improve risk stratification in MI patients. 
Metabolite concentrations can vary greatly over time and are highly sensitive to 
environmental influences. Lipid profiles have been shown to change shortly after MI and 
only gradually return to baseline after several weeks.15 The predictive value of a biomarker 
may thus vary over time. We therefore studied metabolic markers of LVEF, ISZ and 
metformin response in the GIPS-III cohort at three different time points: baseline (on 
admission), 24 h post-MI and 4 months post-MI.  
The objective of this ancillary study of the GIPS-III trial was to evaluate the effect of 
metformin on metabolic profiles in non-diabetic STEMI patients and to identify prognostic 
markers, which predict LVEF and ISZ 4 months post-MI. Furthermore we tested whether 
metformin improved LVEF and ISZ in subgroups of patients, as identified by metabolic 





The GIPS-III study is a randomized trial that included 380 non-diabetic patients undergoing 
primary PCI for ST segment elevation myocardial infarction. Participants received a 4-month 
regimen with either metformin 500mg 2dd1 or matching placebo 2dd1. The design of the 
study has been previously described in more detail.4,5 All patients provided written informed 
consent. The study complied with the Declaration of Helsinki and was approved by the ethics 
committee of the University Medical Center Groningen (the Netherlands) and national 
authorities (NCT01217307). The primary outcome measure was LVEF, the secondary 
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outcome measure was ISZ. Both measures were assessed 4 months post-MI by MRI as 
described below.  
 
Laboratory Measurements 
Non-fasting blood samples were obtained on admission (N=339), 24 h post-MI (N=329) and 
4 months post-MI (N=316). Serum and EDTA-anticoagulated plasma samples were stored at 
− 80 °C until analyzed. Metabolic profiling was performed using a high-throughput 1H NMR 
metabolomics platform.16 We obtained a total of 233 serum metabolite concentrations and 
ratios, including 168 lipoprotein subclass measures, 45 lipid related measures, 5 glycolysis 
related metabolites, 9 amino acids, 3 ketone bodies, 2 fluid balance related metabolites and 1 
inflammatory marker. An overview of all metabolite measures is given in Supplemental 
Table 1. 
 
Cardiac Magnetic Resonance imaging (CMR) 
LVEF and ISZ were measured by cardiac magnetic resonance imaging (MRI) 4 months after 
MI as previously described in detail.4,5 Independent cardiologists analyzed all MRI data and 
assessed LVEF and ISZ, blinded for treatment assignment. 
 
Statistical analysis 
Missing metabolite measures were imputed using random forest imputation as implemented 
in the R package missForest.17 Since most metabolite measures showed skewed distributions, 
they were normalized using rank-based inverse normal transformation within each time point 
separately. Spearman’s correlation coefficients were calculated from the metabolite 
concentrations for each time point (baseline, 24 h post-MI and 4 months post-MI) and plotted 
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using the corrplot function of the corrplot package of R. The correlation plots are presented in 
Supplemental Figure 1.  
Since many metabolites were highly correlated, principal component analysis (PCA) was 
applied to estimate the number of independent tests for multiple testing correction, using the 
prcomp-function in R. To additionally account for multiple testing at different time points, 
principal components (PCs) were calculated across all three time points. The first 68 PCs 
explained over 95% of the variation in the metabolite data, yielding an adjusted significance 
level of p<0.05/68 = 0.00074. 
Unpaired t-tests were performed to assess the effect of metformin treatment on metabolite 
measures. To identify biomarkers predictive of LVEF and ISZ, we analyzed all metabolite 
measures at each time point separately, using linear regression adjusted for known predictors 
of ventricular function and medication use: age, sex, baseline N-terminal prohormone of 
brain natriuretic peptide (NTproBNP) levels, baseline creatine kinase (CK)-MB levels, 
myocardial blush grade, metformin treatment and statin treatment (4 months post-MI). To 
meet the assumption of normality of residuals, we tested different transformations. Since 
square-root transformation provided the best results, ISZ was square-root transformed. In 
addition we performed stratified analyses for LVEF and ISZ. According to current 
guidelines18, LVEF 52%-72% was categorized as normal ventricular function; LVEF 41-51% 
was defined as mildly abnormal and LVEF<41% as abnormal for men. Categories were 
LVEF 54%-74% for normal ventricular function, LVEF 41-53% as mildly abnormal and 
LVEF<41% for abnormal for women. ISZ was stratified by tertiles to obtain the same 
number of strata as with LVEF. Associations of metabolite measures with LVEF categories 
and ISZ tertiles were assessed using multinomial logistic regression, which provides pairwise 
comparisons between each level of the outcome variable and a reference level. Finally we 
added the interaction term of metformin treatment and metabolite measure to the linear 
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regression models to identify subgroups of patients in whom metformin was effective. R 




Patient characteristics and metabolite measures 
A total of 380 patients received either metformin placebo treatment. Of these, 109 did not 
undergo MRI 4 months post-MI or did not provide utilizable scans due to insufficient quality. 
Details on metformin/placebo treatment, clinical parameters and conventional lipid and 
(apo)lipoprotein measures have been published elsewhere.5,11  Briefly, metformin treatment 
resulted in a modest decrease in low-density lipoprotein cholesterol (LDL-C) without 
significant effects on total cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, apolipoprotein B (apoB) and apolipoprotein A-I (apoA1) when the values after 
4 months and after 24 h were compared (data not shown).14 Metabolic profiles were 
quantified in a total of 376 patients. Baseline, 24 h post-MI and 4-month post-MI 
measurements were available from 339, 326 and 316 patients, respectively. Premature 
dropout was neither related to metformin treatment, nor to mortality as none of the 
participants died before MRI.5 A summary of all metabolite measures can be found in 
Supplemental Table 1. The correlation matrices revealed substantial correlation within 
lipoprotein subclasses, between amino acids and between fatty acids (Supplemental Figure 
1).  
 
Association of metabolites with LVEF and ISZ 
Results for all metabolite measures tested are shown in Supplemental Tables 2-7. None of the 
metabolite measures was significantly associated with LVEF 4 months post-MI. No baseline 
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metabolite measure predicted LVEF. Patients with higher HDL-TG levels 24 h post-MI 
showed significantly better LVEF (β=1.90 [95% CI: 0.82, 2.97]; p=6.4x10-4) after adjustment 
for metformin treatment, age, sex, baseline NTproBNP levels, baseline CK-MB levels, 
myocardial blush grade and statin use (Table 1A). When LVEF was entered as categorical 
variable (normal, mildly abnormal, abnormal ventricular function), 24 h post-MI 
measurements of HDL-TG (OR=0.36 [95% CI: 0.21, 0.61]; p=1.8x10-4), medium (M-) HDL-
TG (OR=0.37 [95% CI: 0.22, 0.63]; p=2.3x10-4) and small (S-) HDL-TG (OR=0.35 [95% CI: 
0.20, 0.61]; p=2.1x10-4) significantly predicted normal vs. abnormal LVEF 4 months post-MI 
(Figure 1, Table 2). Notably, all HDL-TG related measures showed a positive association 
with LVEF, suggesting a beneficial effect of increased triglyceride content in HDL. We 
found no association of 24-h post-MI measurements with mildly abnormal LVEF relative to 
normal LVEF. In addition, 24 h post-MI measurements of triglycerides (OR=0.39 [95% CI: 
0.23, 0.66]; p=5.2x10-4) and the cholesterol (OR=2.52 [95% CI: 1.48, 4.30]; p=6.6x10-4) in 
very small (XS-) very low-density lipoprotein (VLDL) particles was associated with 
abnormal LVEF compared to normal left ventricular function. Finally, baseline 
measurements of the TG to total lipids ratio in large (L) LDL predicted abnormal LVEF 
(OR=0.37 [95% CI: 0.21, 0.65]; p=6.2x10-4). Addition of a treatment x metabolite interaction 
term did not reveal any patient subgroup in whom metformin improved LVEF (Table 1B). 
We did not find any association between metabolite measures and ISZ at baseline and 4 
months post-MI. In the adjusted model, HDL-TG (β=-0.41 [95% CI: -0.60, -0.22]; p=3.2x10-
5), M-HDL-TG (β=-0.40 [95% CI: -0.60, -0.21]; p=6.4x2x10-5), XL-HDL-TG% (β=-0.38 
[95% CI: -0.58, -0.18]; p=2.7x10-4) and S-HDL-TG (β=-0.34 [95% CI: -0.54, -0.15]; 
p=7.3x10-4) were significantly associated with ISZ 24 h post-MI (Table 1A). In addition, 
phenylalanine (β=0.38 [95% CI: 0.18, 0.58]; p=1.9x10-4) and albumin (β=-0.33 [95% CI: -
0.52, -0.15]; p=5.2x10-4) reached significance in the unadjusted model, but not in the adjusted 
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model. Similarly, 24 h post-MI measurements of HDL-TG (OR=0.48 [95% CI: 0.33, 0.69]; 
p=9.2x10-5), M-HDL-TG (OR=0.46 [95% CI: 0.31, 0.67]; p=6.2x10-5), S-HDL-TG 
(OR=0.51 [95% CI: 0.35, 0.74]; p=3.9x10-4) and XL-HDL-TG% (OR=0.49 [95% CI: 0.33, 
0.72]; p=3.2x10-4) predicted ISZ, when the first tertile was compared to the third tertile 
(Figure 2, Table 2). Again, our findings suggest a beneficial effect of higher HDL-TG levels. 
We found no significant treatment x metabolite interactions (Table 1B). 
As shown in Supplemental Table 8, HDL-TG, M-HDL-TG, S-HDL-TG and XL-HDL-
TG% increased between baseline and 24 h post-MI and remained relatively stable between 24 
h and 4 months post-MI, except for XL-HDL-TG% which showed a moderate gain. Similar 
to HDL-TG, serum triglyceride levels increased between baseline and 24 h post-MI, but were 
decreased 4 months after MI.  
 
Effects of metformin of metabolic profiles 
Results for all metabolite measures are shown in Supplemental Table 9. To assess baseline 
differences in metabolic profiles, we compared metabolite measures between the treatment 
group and controls at baseline. We did not find any difference between the two groups at 
baseline. Table 3 summarizes metabolic measurements for 24 h post-MI and 4 months post-
MI. 24 h post-MI, after the first doses of the treatment had been administered, both alanine 
(median: 0.49 mmol/L vs. 0.46 mmol/L; p=9.0x10-4) and pyruvate (median: 0.16 mmol/L vs. 
0.14 mmol/L; p=0.001) displayed trends towards increased concentrations in the metformin 
group. After the 4-month treatment period, alanine levels were significantly elevated in 
metformin-treated patients (median: 0.46 mmol/L vs. 0.44 mmol/L; p=2.4x10-4) as shown in 
Table 3. In addition, the phospholipids to total lipids ratio in very large high density 
lipoprotein (XL-HDL) particles (XL-HDL-PL%) was significantly reduced in the metformin 





We used 1H NMR spectrometry-based metabolite measures to evaluate the effects of 
metformin on metabolic profiles of non-diabetic MI patients and to study prognostic 
metabolites predicting LVEF and ISZ 4 months post-MI. Moreover we investigated whether 
metabolic profiling could be used to identify subgroups of patients in whom metformin was 
effective. After the 4-month treatment period, we found higher alanine levels and lower XL-
HDL-PL% in metformin-treated patients as compared to controls. Remarkably, higher 
triglyceride levels in HDL and several HDL subfractions measured 24 h post-MI were 
associated with favorable outcome as inferred from higher LVEF and smaller ISZ 4 months 
post-MI. Moreover, categorical analysis of LVEF revealed that besides HDL-TG, the 
composition of XS-VLDL (24 h post-MI) and L-LDL (baseline) was associated with 
abnormal left ventricular function 4 months post-MI. We could not identify metabolic 
profiles associated with treatment benefits from metformin. 
Similar to our results, the CAMERA study, a clinical trial investigating the effects of 
metformin on different amino acids, found substantially increased alanine levels 18 months 
after treatment onset.13 Alanine plays a crucial role in the alanine-glucose cycle, in which 
alanine released by muscle tissue is transported to the liver before it is converted into 
pyruvate for gluconeogenesis. Findings from animal studies suggest that metformin reduces 
gluconeogenesis by inhibiting hepatic alanine uptake19 and by hampering fat-induced 
changes in the glycolysis metabolic pathway20. As a result of reduced uptake into the liver, 
blood alanine levels may rise in metformin-treated patients. Interestingly, we observed a 
trend towards increased alanine levels in the metformin group 24 h post-MI,,suggesting rapid 
effects of metformin on gluconeogenesis. 
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Numerous randomized controlled trials have studied the effects of metformin treatment on 
lipid levels in patients with type 2 diabetes. A recent study in diabetic patients found that 
metformin lowered total cholesterol and LDL-C.21 Another study in patients at risk for 
diabetes reported changes in lipoprotein subclasses after one year of metformin treatment, 
with reduced particle concentrations of small LDL and elevated large LDL, small HDL and 
large HDL.9  In our recent report, we observed modest decreases in LDL cholesterol, no 
change in apolipoprotein B, and as a result a small decrease in LDL particle size.11 In the 
present study which used a different NMR-based method, only the phospholipid content of 
large HDL particles was decreased in response to metformin.  
We also tested whether lipoprotein characteristics and metabolite measures at baseline, 24 
h post-MI and 4 months post-MI were associated with 4 months post-MI LVEF and ISZ. We 
found that increased HDL-TG levels measured 24 h post-MI were associated with a greater 
LVEF. In addition, decreased HDL-TG, M-HDL-TG, XL-HDL-TG% and S-HDL-TG 
measured 24 h post-MI predicted higher ISZ. Categorical analysis of LVEF and ISZ provided 
similar results with more favorable outcomes for patients with higher HDL-TG levels. No 
metabolite measure showed a significant interaction with metformin treatment, suggesting 
that there was no metabolic subgroup of patients in whom metformin was effective.  
Our findings suggest beneficial effects of higher triglyceride levels in HDL and in HDL 
subfractions measured 24 h post-MI on ISZ and LVEF. Clinical studies identified low 
admission triglyceride levels as a risk factor for recurrent CV events and mortality in STEMI 
patients.22,23 Likewise, low triglyceride levels are associated with a poor prognosis in stroke 
patients.24 This contrasts with findings from large-scale case-control and prospective cohort 
studies indicating that hypertriglycemia is a strong predictor of CV events, even independent 
of cholesterol levels.25,26 These epidemiological findings, however, apply to individuals who 
were not studied during the course of an acute coronary event. Similarly paradoxical findings 
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have been obtained for plasma cholesterol levels. While hypercholesterolemia is an 
established CV risk factor in the general population, admission LDL-C levels < 70 mg/dl are 
associated with higher mortality and incidence of heart failure in statin-naïve STEMI 
patients.27 The pathogenic mechanisms underlying recurrent CV events shortly after an acute 
event are still poorly understood. It is possible that in the acute setting HDL-TG plays a 
distinct role on CV outcome . 
VLDL is the most important triglyceride carrier in plasma. The triglyceride content of 
VLDL showed substantial correlation with HDL-TG 24 h post-MI (Supplemental Figure 1 
B). However, only the triglyceride content of very small VLDL particles was associated with 
LVEF categories. In addition, the TG content of large LDL particles at baseline predicted 
abnormal LVEF 4 months post-MI. Inhibition of fatty acid uptake by relocation of 
FAT/CD36 may reduce intracellular fatty acid concentrations28, resulting in increased 
extracellular fatty acid levels and diminished lipolysis of lipid-bound triglycerides. This may 
initially lead to triglyceride enrichment of VLDL and LDL particles, which subsequently 
transfer excess triglycerides to HDL particles in exchange for cholesteryl esters by the action 
of cholesteryl ester transfer protein (CETP), thereby increasing the triglyceride content in 
HDL.29 In line with this, blood samples of MI patients collected immediately after diagnosis 
show strong triglyceride enrichment of HDL2 particles.
30  Higher plasma HDL-TG levels 
could thus be consequent to inhibition of fatty acid uptake, and coincide with diminished 
fatty acid oxidation and prevention of further myocardial damage.31  Larger triglyceride-rich 
particles are converted  to small VLDL subfractions as a result of lipase-mediated 
delipidation32,  suggesting that triglyceride enrichment may be secondary to initial 
triglyceride uptake of large VLDL. Larger VLDL particles may be delipidated rapidly, which 
may explain why the association of triglycerides with LVEF was limited to very small VLDL 
24 h post-MI. Similarly, a major proportion of LDL-TG is derived from large VLDL32, which 
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may partly result from CETP-mediated delipidation of large VLDL. Taken together, early 
metabolic changes after MI could reflect adaptive mechanisms that promote functional 
recovery. 
While we observed associations of LVEF categories with 24 h post-MI measurements of XS-
VLDL-TG% and XS-VLDL-C%, these metabolite measures did not significantly predict 
LVEF when LVEF was analyzed as a continuous variable. However, the regression model 
with continuous outcome assumes linearity between metabolite measures and LVEF, whereas 
categorical analysis of LVEF in combination with multinomial logistic regression renders the 
model sensitive to non-linear associations. As shown in Figure 2 A, HDL-TG, M-HDL-TG 
and S-HDL-TG follow a linear trend across the three LVEF categories, whereas XS-VLDL-
TG% and XS-VLDL-C% display non-linear trends. 
 
Limitations 
The GIPS-III trial was originally designed to assess differences in LVEF between metformin 
treated patients controls. We conducted 68 independent tests, raising the possibility that our 
study was not powered to detect smaller changes. However, we were able to detect a 
significant effect for alanine levels, which were only slightly increased in the metformin 
group (median difference: 0.03 mmol/L), demonstrating sufficient power to perform a 
metabolic profiling analysis. In addition, all patients received intravenous heparin before PCI 
when baseline blood samples were drawn. Heparin stimulates lipolysis and hence acutely 
reduces plasma triglyceride levels33, which is in line with the marked increase in triglyceride 
levels between baseline and the other time points (Supplemental Table 8). STEMI patients 
routinely receive heparin before PCI, rendering the results for baseline measurements 
relevant to clinical settings. These findings measurements should nevertheless be interpreted 
with caution. Moreover, we performed metabolic profiling in non-fasting blood samples, 
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warranting further research to substantiate our findings under fasting conditions. However, 
the NMR platform used in our study mainly quantifies lipid measures, which change only 
slightly after food consumption and show similar associations with cardiovascular risk in 
fasting and non-fasting individuals.34  
 
Conclusions 
In summary, our study suggests that metformin treatment started directly after presentation 
with STEMI produces changes in alanine and XL-HDL-PL% as assessed after 4 months. 
Higher triglyceride levels in HDL and in HDL subfractions measured 24 h post-MI were 
predictive of better LVEF and smaller ISZ 4 months post-MI. HDL-TG may thus serve as an 
early biomarker of left ventricular dysfunction in STEMI patients. However, further studies 
are required to substantiate the clinical significance of HDL-TG in CV risk prediction and to 
investigate the biological mechanism underlying associations of metabolic biomarkers with 
recurrent CV events. Our findings emphasize the utility of high-throughput metabolic 
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 Unadjusted model  Adjusted model 
Metabolite β [95% CI] p   β [95% CI] p 
      
LVEF (N=245)      
HDL-TG 1.84 [0.78, 2.89] 7.4x10-4  1.90 [0.82, 2.97] 6.4x10-4 
M-HDL-TG 1.70 [0.65, 2.75] 0.002  1.65 [0.55, 2.74] 0.003 
XL-HDL-TG% 1.67 [0.56, 2.77] 0.003  1.82 [0.68, 2.96] 0.002 
S-HDL-TG  1.51 [0.45, 2.57] 0.006   1.68 [0.58, 2.78] 0.003 
Albumin 1.10 [0.04, 2.16] 0.044  1.25 [0.10, 2.40] 0.034 
Phenylalanine   -0.90 [-2.01, 0.21] 0.113  -0.55 [-1.68, 0.58] 0.344 
      
ISZ (N=231)      
HDL-TG  -0.42 [-0.60, -0.24] 1.2x10-5   -0.41 [-0.60, -0.22] 3.2x10-5 
M-HDL-TG  -0.42 [-0.60, -0.23] 1.4x10-5   -0.40 [-0.60, -0.21] 6.4x10-5 
XL-HDL-TG%  -0.37 [-0.56, -0.18] 1.9x10-4   -0.38 [-0.58, -0.18] 2.7x10-4 
S-HDL-TG  -0.33 [-0.52, -0.14] 6.8x10-4   -0.34 [-0.54, -0.15] 7.3x10-4 
Albumin  -0.33 [-0.52, -0.15] 5.2x10-4   -0.33 [-0.54, -0.13] 0.002 





 Unadjusted model  Adjusted model 
Metabolite β [95% CI] p   β [95% CI] p 
      
LVEF (N=245)      
Treatment X      
HDL-TG 1.15 [-0.96, 3.26] 0.285  0.94 [-1.18, 3.06] 0.387 
M-HDL-TG 1.09 [-1.01, 3.19] 0.311  0.82 [-1.30, 2.94] 0.449 
XL-HDL-TG% 0.71 [-1.50, 2.92] 0.529  0.60 [-1.61, 2.82] 0.593 
S-HDL-TG  0.73 [-1.42, 2.87] 0.506   0.68 [-1.46, 2.82] 0.534 
Albumin 0.36 [-1.77, 2.49] 0.740  0.38 [-1.74, 2.51] 0.725 
Phenylalanine   -1.02 [-3.25, 1.22] 0.373  -1.24 [-3.51, 1.03] 0.286 
      
ISZ (N=231)      
Treatment X      
HDL-TG  -0.07 [-0.44, -0.30] 0.701   -0.04 [-0.41, 0.34] 0.856 
M-HDL-TG  -0.19 [-0.56, 0.18] 0.316   -0.14 [-0.52, 0.24] 0.465 
XL-HDL-TG%  0.04 [-0.35, 0.42] 0.849   0.04 [-0.35, 0.44] 0.827 
S-HDL-TG  -0.04 [-0.42, 0.35] 0.857   -0.03 [-0.41, 0.36] 0.891 
Albumin  -0.06 [-0.43, 0.32] 0.762   -0.05 [-0.43, 0.33] 0.804 
Phenylalanine 0.01 [-0.39, 0.40] 0.977    0.04 [-0.36, 0.45] 0.834 
 
Table 1A:  Association of selected metabolite measures with LVEF and ISZ 24 h post-MI. Results are shown for 
the unadjusted model and the adjusted model including age, sex, treatment, statin use, CKMB, NTproBNP and 
MBG as covariates. Table 1B: Association of treatment x metabolite interaction for selected metabolites. Results 
are shown for the unadjusted model (main effects and interaction term) and adjusted model including age, sex, 
statin use, CKMB, NTproBNP and MBG as covariates. Effects significant after correction for multiple testing 
(p<7.4x10-4) are highlighted in bold. CI: confidence interval; LVEF: left ventricular ejection fraction; ISZ: infarct 
size; HDL-TG: triglycerides in HDL particles; M-HDL-TG: triglycerides in medium HDL particles; XL-HDL-































Table 2:  Associations of metabolite measures 24 h post-MI with LVEF categories (normal, mildly abnormal, 
abnormal) and ISZ (tertiles) categories, adjusted for age, sex, treatment, statin use, CKMB, NTproBNP and MBG. 
Results for pairwise comparisons are given. Metabolites with at least one significant pairwise between-group 
comparison are shown. Effects significant after correction for multiple testing (p<7.4x10-4) are highlighted in 
bold. CI: confidence interval; LVEF: left ventricular ejection fraction; ISZ: infarct size; L-LDL-TG%: triglyceride 
to total lipids ratio in large LDL particles; HDL-TG: triglycerides in HDL particles; M-HDL-TG: triglycerides in 
medium HDL particles; S-HDL-TG: triglycerides in small HDL particles; XL-HDL-TG%: triglycerides to total 
lipids ratio in very large HDL particles; XS-VLDL-TG%: triglycerides to total lipids ratio in very small VLDL 












Metabolite OR [95% CI] p   OR [95% CI] p 
LVEF normal vs.  
mildly abnormal  
normal vs.  
abnormal 
Baseline      
L-LDL-TG% 1.05 [0.76, 1.45] 0.774  0.37 [0.21, 0.65] 6.2x10-4 
      
24 h post-MI      
HDL-TG 0.70 [0.51, 0.96] 0.027  0.36 [0.21, 0.61] 1.8x10
-4 
M-HDL-TG 0.72 [0.52, 1.00] 0.050  0.37 [0.22, 0.63] 2.3x10
-4 
S-HDL-TG 0.74 [0.53, 1.02] 0.062  0.35 [0.20, 0.61] 2.1x10
-4 
XS-VLDL-TG% 0.83 [0.61, 1.14] 0.247  0.39 [0.23, 0.66] 5.2x10
-4 
XS-VLDL-C% 1.10 [0.82, 1.49] 0.523   2.52 [1.48, 4.30] 6.6x10
-4 
      
ISZ 1st tertile vs.  
2nd tertile  
1st tertile vs. 
 3rd tertile 
24 h post-MI      
HDL-TG 0.78 [0.55, 1.11] 0.169  0.48 [0.33, 0.69] 9.2x10
-5 
M-HDL-TG 0.88 [0.62, 1.25] 0.472  0.46 [0.31, 0.67] 6.2x10
-5 
S-HDL-TG 0.92 [0.64, 1.30] 0.621  0.51 [0.35, 0.74] 3.9x10
-4 
XL-HDL-TG% 0.75 [0.52, 1.07] 0.116   0.49 [0.33, 0.72] 3.2x10-4 
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 Placebo   Metformin   
Metabolite Median (IQR) Median (IQR) p 
24 h  N=170 N=159  
Alanine in mmol/l 0.46 (0.09) 0.49 (0.09) 9.0x10-4 
Pyruvate in mmol/l 0.14 (0.05) 0.16 (0.07) 0.001 
XL-HDL-PL%  36.11 (17.52) 33.98 (14.65) 0.908 
4 months  N=159 N=157  
Alanine in mmol/l 0.44 (0.08) 0.46 (0.09) 2.4x10-4 
Pyruvate in mmol/l 0.10 (0.04) 0.11 (0.04) 0.006 
XL-HDL-PL%  38.79 (19.50) 28.89 (23.90) 7.5x10-5 
 
Table 3:  Effects of treatment on selected metabolite measures 24 h post-MI and 4 months post-MI. Significant 
effects (p<7.4x10-4) are highlighted in bold. IQR: inter-quartile range; XL-HDL-PL%: phospholipids to total 







































Figure 1: Box plots comparing selected metabolite measures (24 h post-MI) between distinct LVEF categories.  
For all plots, the lower and the upper margins represent the first and third quartile, respectively. Vertical lines 
indicate median values; squares indicate mean values. The whiskers represent the lowest and the highest value 
within 1.5 IQR. Differences between categories were assessed using multinomial logistic regression adjusted for 
treatment, age, sex, NTproBNP levels, CK-MB levels, myocardial blush grade, statin use. Asterisks indicate 
effects significant after correction for multiple testing (p<7.4x10-4). IQR: inter-quartile range; LVEF: left 
ventricular ejection fraction; ISZ: infarct size; HDL-TG: triglycerides in HDL particles; M-HDL-TG: triglycerides 
in medium HDL particles; XL- S-HDL-TG: triglycerides in small HDL particles; XS-VLDL-TG%: triglycerides 
























Figure 2: Box plots comparing selected metabolite measures (24 h post-MI) between ISZ tertiles.  For all plots 
plots, the lower and the upper margins represent the first and third quartile, respectively. Vertical lines indicate 
median values; squares indicate mean values. The whiskers represent the lowest and the highest value within 1.5 
IQR. Differences between categories were assessed using multinomial logistic regression adjusted for treatment, 
age, sex, NTproBNP levels, CK-MB levels, myocardial blush grade, statin use. Asterisks indicate effects 
significant after correction for multiple testing (p<7.4x10-4). IQR: inter-quartile range; LVEF: left ventricular 
ejection fraction; ISZ: infarct size; HDL-TG: triglycerides in HDL particles; M-HDL-TG: triglycerides in medium 
HDL particles; XL- S-HDL-TG: triglycerides in small HDL particles; XL-HDL-TG: triglyceride to total lipids 
ratio in very large HDL particles. 
 
 
 
